These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38589675)

  • 1. PDIA2 has a dual function in promoting androgen deprivation therapy induced venous thrombosis events and castrate resistant prostate cancer progression.
    Li Y; Lv L; Ye M; Xie N; Fazli L; Wang Y; Wang W; Yang S; Ni Q; Chen J; Guo X; Zhao Y; Xue G; Sha J; Dong X; Zhang L
    Oncogene; 2024 May; 43(21):1631-1643. PubMed ID: 38589675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel.
    Labanca E; Bizzotto J; Sanchis P; Anselmino N; Yang J; Shepherd PDA; Paez A; Antico-Arciuch V; Lage-Vickers S; Hoang AG; Tang X; Raso MG; Titus M; Efstathiou E; Cotignola J; Araujo J; Logothetis C; Vazquez E; Navone N; Gueron G
    Oncogene; 2021 Nov; 40(44):6284-6298. PubMed ID: 34584218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor dampens tissue factor expression via nuclear factor-κB and early growth response protein 1.
    Hoesel B; Mussbacher M; Dikorman B; Salzmann M; Assinger A; Hell L; Thaler J; Basílio J; Moser B; Resch U; Paar H; Mackman N; Schmid JA
    J Thromb Haemost; 2018 Apr; 16(4):749-758. PubMed ID: 29427323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
    O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
    Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance.
    Miller DR; Ingersoll MA; Chatterjee A; Baker B; Shrishrimal S; Kosmacek EA; Zhu Y; Cheng PW; Oberley-Deegan RE; Lin MF
    Free Radic Biol Med; 2019 Aug; 139():24-34. PubMed ID: 31100478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TXNDC9 regulates oxidative stress-induced androgen receptor signaling to promote prostate cancer progression.
    Feng T; Zhao R; Sun F; Lu Q; Wang X; Hu J; Wang S; Gao L; Zhou Q; Xiong X; Dong X; Wang L; Han B
    Oncogene; 2020 Jan; 39(2):356-367. PubMed ID: 31477836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen deprivation‑induced OPHN1 amplification promotes castration‑resistant prostate cancer.
    Liu J; Zhang Y; Li S; Sun F; Wang G; Wei D; Yang T; Gu S
    Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34738630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion.
    Shih TC; Liu R; Wu CT; Li X; Xiao W; Deng X; Kiss S; Wang T; Chen XJ; Carney R; Kung HJ; Duan Y; Ghosh PM; Lam KS
    Clin Cancer Res; 2018 Sep; 24(17):4319-4331. PubMed ID: 29666302
    [No Abstract]   [Full Text] [Related]  

  • 11. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
    Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
    Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
    Wadosky KM; Koochekpour S
    Oncotarget; 2016 Sep; 7(39):64447-64470. PubMed ID: 27487144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
    Yao M; Shi X; Li Y; Xiao Y; Butler W; Huang Y; Du L; Wu T; Bian X; Shi G; Ye D; Fu G; Wang J; Ren S
    Cell Death Dis; 2020 Aug; 11(8):638. PubMed ID: 32801300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-6 induced overexpression of valosin-containing protein (VCP)/p97 is associated with androgen-independent prostate cancer (AIPC) progression.
    Duscharla D; Reddy Kami Reddy K; Dasari C; Bhukya S; Ummanni R
    J Cell Physiol; 2018 Oct; 233(10):7148-7164. PubMed ID: 29693262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of the HOXA10 gene during castrate-resistant prostate cancer progression.
    Long Z; Li Y; Gan Y; Zhao D; Wang G; Xie N; Lovnicki JM; Fazli L; Cao Q; Chen K; Dong X
    Endocr Relat Cancer; 2019 Mar; 26(3):279-292. PubMed ID: 30667363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
    J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
    Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
    Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
    [No Abstract]   [Full Text] [Related]  

  • 20. FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.
    Jones D; Wade M; Nakjang S; Chaytor L; Grey J; Robson CN; Gaughan L
    Oncotarget; 2015 Oct; 6(30):29782-94. PubMed ID: 26336819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.